SCHEMBL23748281

SCHEMBL23748281

C=CCCNC(=O)c1[nH]ccc(=O)c1OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
ALDH1A1 P00352 3/20 0.38
USP2 O75604 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 2/20 0.37
NSD2 O96028 1/20 0.37
ABL1 P00519 1/20 0.37
PPARG P37231 1/20 0.37
RIN1 Q13671 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
SPHK2 Q9NRA0 2/20 0.36
SPHK1 Q9NYA1 1/20 0.36
LMNA P02545 2/20 0.36
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748352 0.94 POLB (0.47) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL24353633 0.93 POLB (0.46) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL23748321 0.89 POLB (0.51) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL24354319 0.87 POLB (0.46) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL23748282 0.81 POLB (0.53) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL10188493 0.80 POLB (0.60) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL24353896 0.80 POLB (0.49) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL21185114 0.80 POLB (0.46) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL10188507 0.80 POLB (0.52) POLBALDH1A1USP2TSHRHSD17B10
SCHEMBL24353890 0.79 POLB (0.51) POLBALDH1A1USP2TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed
CN-113195502-A Macrocyclic influenza endonuclease inhibitors 詹森生物制药有限公司 2021-07-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 POLB 74/4885ALDH1A1 2073/4885USP2 2019/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP POLB 32/4885ALDH1A1 1487/4885USP2 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.